Key facts
- It has raised $21.0M across 1 recorded rounds; the latest was Early Stage VC ($5.1M) in Dec 2021.
- Notable investors include Medical Excellence Capital, The ALS Association.
- ProJenX has filed 1 Form D with the SEC, most recently Jan 2022 ($5.1M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for ProJenX
Funding rounds
1 roundsAbout ProJenX
Operator of a clinical-stage biopharmaceutical company intended to treat neurodegenerative diseases. The company develops oral, brain-penetrant, small molecules shown in multiple laboratory models that target motor neuron degenerative pathways to slow or prevent disease progression, enabling physicians to promote endoplasmic reticulum stress-mediated motor neuron loss for patients with these debilitating conditions.
- Sector
- Healthcare
- HQ
- Nissequogue, NY, United States
- Founded
- 2021
- Employees
- 7
- Website
- projenx.com/
- Ownership
- Privately Held (backing)
ProJenX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProJenX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProJenX in its N-PORT filings yet. We sweep new filings monthly.